Micellar drug carriers: a new modeling platform for better cancer therapies
Official title: DMS/NIGMS 2: Multiscale modeling of stimuli responsive drug delivery systems
Funded at University of South Carolina at Columbia · NIH-11394898 · Data updated 2026-11-12
Researchers will build a computer-based platform to predict how micellar drug carriers behave in the body, helping tailor cancer treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of South Carolina at Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | September 1, 2025 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $297,538 |
| NIH project number | 5R01GM163240-02 |
| Project ID | NIH-11394898 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients whose cancer treatment may involve micellar or similar nanoparticle drug delivery systems assessed by clinicians.
✕Less likely to help
Patients not receiving micellar-based therapies or those not involved in research that informs micellar design may see no direct benefit.
What this research studies
This project creates a advanced modeling and simulation tool to understand how micelles—tiny drug carriers—change shape and flow in different body conditions. It combines theory, computer simulations, and lab data to predict how drugs release from micelles under varying pH and flow. The team will validate the model with real-world experimental results to ensure reliable predictions. The goal is to speed up the design of more effective micellar drug delivery systems for cancer therapy.
Why it matters
Potential benefit: If successful, patients could benefit from more accurate drug release predictions and faster development of targeted cancer therapies.
How similar studies have gone: Preclinical studies using micellar systems have shown promise, but this project focuses on an integrated modeling platform to forecast behavior under physiological conditions.
Where this research is happening
-
University of South Carolina at Columbia
Columbia, United States Active
Researchers
- Principal investigator: Vasquez, Paula — University of South Carolina at Columbia
- Study coordinator: Vasquez, Paula
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.